Motif Bio Share Discussion Threads

[encarter] 02/3/2018 08:10

Unless they have a discounted placing.

[blueblood] 02/3/2018 07:35

AMP extended all debt facilities until December 2018 so no forced selling before FDA decision. Really good news for share price over rest of year imho!

[ny boy] 01/3/2018 12:45

This is one I am looking at again but for now just waiting for (IMM) to release top line phase 3 results later this month before committing funds here.

[1renard] 01/3/2018 10:34

what are the performance conditions?

[ssrover] 01/3/2018 08:52

they don't need to do anything to excersise the options though.

i can't see that being bullish

[chadders] 01/3/2018 08:46

Exactly, so not discounted and linked to performance

[ssrover] 01/3/2018 08:16

hows that bullish? onions same price as current share price

[chadders] 01/3/2018 07:27

Very positive sign for me

[blueblood] 01/3/2018 07:16

Senior Managements options at 36.1p. Not bad at all and GLs are dependent on performance. All aligned for NDA submission in next few weeks.

[chadders] 28/2/2018 15:20

A couple of larger trades today I notice.

[ohisay] 22/2/2018 02:34

Still plenty going on with the company...

[encarter] 13/2/2018 14:07

AMP will be off loading more stock in June so no chance of a decent rise until after then.

[librayang0925] 10/2/2018 09:46

Why the large fall on Friday.

[seans66] 09/2/2018 10:47

Topped up.

[l4z4rus] 06/2/2018 11:02

Good old Motif, as contrary as ever

[small crow] 06/2/2018 10:55

"Methinks". Old English. Only ever seen in Shakespeare and Financial websites. Why? No-one knows, forsooth and thrice Yea.

[chadders] 06/2/2018 10:25

Is that blue I see in my sea of red? If it holds it'll be quite a bullish statement methinks.

[longshanks] 06/2/2018 10:24

A rare spot of blue whilst murder is all around on the market dance floor

[gclark] 06/2/2018 08:49

Nothing is guaranteed timw3 but there are reasons to believe they will approve:

evidence is there of non-inferiority to vancomycin, which doesn't sound great but in reality is pretty good in an age of growing resistance

government policies to encourage the development of new antibiotics, and not approving a new one might discourage further investment in new antibiotics and lead to adverse publicity for the FDA and the experts

a particular role for Iclaprim in obese and renally impaired patients with ABSSSI where dose adjustment may not be necessary compared to vancomycin

a less used mode of action which should make the development of resistance less of an issue, but of course it is still an issue, and makes it an alternative to use where there is resistance to vancomycin

I am invested here and believe in the future of iclaprim. Also the potential use in other indications is important for the future. I am also impressed with the management of the company and the materials they are producing.

I have said on another BB that even an idiot management team can be successful if the drug works and meets an unmet need, but now having seen what I regard as such a team in another company I can see how even a good drug and returns to shareholders can be delayed and lost in such cases. I have confidence in this team at Motif Bio. They are doing the right things, in my view.

[escapetohome] 06/2/2018 08:00

Down 4.6% i would call that a healthy correction!!

And one that is very much needed for sustainability, hopefully a crash will be avoided!!!!!!!!

[timw3] 06/2/2018 07:56

going back to 20p imo

FDA approval not guaranteed neither.

OUCH

[timw3] 05/2/2018 21:56

hate trader you not scoring points down your local trying to get the bulls eye!! i know who you are son!!

[flavio_monteiro] 05/2/2018 21:03

Tim, it doesn’t look like an ugly chart to me...read them properly...lots of support at 35.5.